[en] PURPOSE: GADIS aims at determining the prevalence of generalized anxiety disorder (GAD) and major depression (MD) in primary care and their impact on the patient's functioning in Belgium and Luxemburg. METHOD: A large scale screening program was conducted at the consultation of general practitioners to detect patients with GAD and MD according to DSM-IV criteria. We collected additional data regarding the use of hypnotic, tranquilizer, antidepressant and analgesic medications. Impact on the patient was assessed with the Sheehan disability scale. RESULTS: Three hundred GP's in Belgium and Luxemburg were asked to screen 50 consecutive patients. Of the 13,677 analyzed patients, 8.3% were diagnosed to have GAD and 6.3% MD. Comorbidity was observed in 4.2% of patients. The prevalence was much higher in the French-speaking part of Belgium. GAD and MD were associated with impairment in social, familial and professional functioning. Only a minority of patients with GAD and/or MD was treated with an antidepressant and almost half of subjects with GAD and/or MD were treated with a tranquilizer. CONCLUSION: Prevalence rates of GAD and MD in primary care in Belgium are comparable to other countries. GAD and MD are disabling conditions. Antidepressants are still used only in a minority of subjects with GAD and/or MD in primary care in Belgium and Luxemburg. The prevalence of GAD and MD appears to be much higher in French-speaking parts of Belgium.
Disciplines :
Psychiatry
Author, co-author :
Ansseau, Marc ; Université de Liège - ULiège > Département des sciences cliniques > Psychiatrie et psychologie médicale
Fischler, Benjamin
Dierick, Michel
Mignon, Annick
Leyman, Sophie
Language :
English
Title :
Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study
Publication date :
May 2005
Journal title :
European Psychiatry
ISSN :
0924-9338
eISSN :
1778-3585
Publisher :
Editions Scientifiques Medicales Elsevier, Paris, France
M. Ansseau, M. Dierick, F. Buntinckx, P. Cnoeckaert, J. De Snedt, and M. Van Den Haute High prevalence of mental disorders in primary care J. Affect. Disord. 78 2004 49 55
A. F́line, and I. Le Goc Les Benzodiaźpines: prescription, consommation, addiction Sem. Hop. 61 1985 3172 3175
A.J. Gelenberg, R.B. Lydiard, R.L. Rudolph, L. Aguiar, J.T. Haskins, and E. Salinas Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder JAMA 283 2000 3082 3088
R.A. Gould, M.W. Otto, M.H. Pollack, and L. Yap Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: a preliminary meta-analysis Behav. Ther. 28 1997 200 210
W.J. Katon, and E.A. Walker Medically unexplained symptoms in primary care J. Clin. Psychiatry 59 Suppl 20 1998 15 21
R.C. Kessler, R.L. Du Pont, P. Berglund, and H.U Wittchen Impairment in pure and comorbid generalized anxiety disorder and major depression at 12:months in two national surveys Am. J. Psychiatry 156 1999 1915 1923
M. Legrain, and T. Lecomte La consommation des psychotropes en France et dans quelques pays euroṕens Bull. Acad. Natl. Med. 181 1997 1073 1084
W. Maier, M. Gaensicke, H.J. Freyberger, M. Linz, R. Henn, and Y. Lecrubier Generalized anxiety disorder (ICD-10) in primary care from a cross-cultural perspective: a valid diagnostic entity? Acta Psychiatr. Scand. 101 2000 29 36
M.M. Ohayon, and M.H. Lader Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom J. Clin. Psychiatry 63 2002 817 825
J. Ormel, M. Von Korff, B. Ustun, S. Pini, A. Korten, and T. Oldehinkel Common mental disorders and disability across culture: results from the WHO collaborative study on psychological problems in general health care JAMA 272 1994 1741 1748
A. Pelissolo, P. Boyer, J.P. Lepine, and J.C. Bisserbe Epid́miologie de la consommation des anxiolytiques et des hypnotiques en France et dans le monde Encephale 22 1996 187 196
J.L. Pestiaux, M. Marques, F. Ketser, M. Pŕvost, and A. Peters Repŕsentation populaire et consommation de tranquilisants 1990 Union Nationale des Mutualit́s Socialistes, Promotion de la Sant́
J. Reggers, and M. Ansseau Lifetime prevalence of DSM-IV psychiatric disorders in the Lìge study: preliminary results Abstracts of the VIII Congress of the International Federation of Psychiatric Epidemiology 1999
N. Sartorius, T.B. Ustun, Y. Lecrubier, and H.U. Wittchen Depression comorbid with anxiety: results from the WHO study on the psychological disorders in primary health care Br. J. Psychiatry 168 Suppl 30 1996 38 43
D.V. Sheehan, K. Harnett-Sheehan, and B.A. Raj The measurement of disability Int. Clin. Psychopharmacol. 11 Suppl 3 1996 89 95
D.V. Sheehan, Y. Lecrubier, K.H. Sheehan, P. Amorim, J. Janavs, and E. Weiller The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 J. Clin. Psychiatry 59 Suppl 20 1998 22 33
V.M. Simonds, and V.E. Whiffen Are gender differences in depression explained by gender differences in comorbid anxiety? J. Affect. Disord. 77 2003 197 202
E. Souetre, H. Lozet, I. Cimarosi, P. Martin, J.M. Chigon, and J. Ad̀s Cost of anxiety disorders: impact of comorbidity J. Psychosom. Res. 38 1994 151 160
T.B. Ustün N. Sartorius Mental illness in general health care: an international study 1995 Wiley Chichester
E. Weiller, J.C. Bisserbe, W. Maier, and Y. Lecrubier Prevalence and recognition of anxiety syndromes in five European primary care settings: a report from the WHO study on psychological problems in general health care Br. J. Psychiatry 173 Suppl 34 1998 18 23
H.U. Wittchen Generalized anxiety disorder: prevalence, burden and cost to society Depression Anxiety 16 2002 162 171
H.U. Wittchen, S. Zhao, R.C. Kessler, and W.W. Eaton DSM-III-R generalized anxiety disorder in the national comorbidity survey Arch. Gen. Psychiatry 51 1994 355 364
